

## **International tuberculosis care transfer form**

	treated in: is relocating to: information about the individual's personal and clinical data. It							
also includes contact information of the treating physic	cians and/or public health authority in the sending country.  y clinical care providers and should not be further transmitted.							
d. D L'accounting								
<ol> <li>Personal information</li> <li>Please indicate if the person with TB agreed to be con</li> </ol>	ntacted at the destination <i>of relocation</i> : Yes No							
Last name:	First name:							
Date of birth:	Gender: Male Female Other							
Nationality:	Language(s) spoken:							
Phone number:	E-mail:							
Relocation address:       □ Available (please provide details below).       □ Not available								
Street name, number:	Contact person at relocation:  Name:							
ZIP code:	Phone number:							
City/village:								
District/province:	• E-mail:							
	Expected transfer date:							
Country:								
2. Description of current TB disease episode								
	TB history:							
, , ,	Date of diagnosis:							
To extrapalitionary TD, piease specify what organs	☐ New TB episode ☐ Previously diagnosed/treated  If previously diagnosed or treated, describe the treatment outcome:							
Imaging results:								
Most recent imaging test (s) performed: ☐ Chest-X-ray	☐ CT scan ☐ Other (specify):							
Most recent imaging results: □ Normal findings □ Abn	normal findings (specifybelow):							
Bacteriological confirmation: Please indicate the m	ost recent results of the laboratory tests performed.							
Test Test performed? Date (dd/mm)	• •							
Microscopy □ yes □ no —	— □positive □negative □pending □unknown							
Culture	—— □positive □negative □pending □unknown							
Genotypic test* ☐ yes ☐ no ——————	□positive □negative □pending □unknown							
Pathogen identified:   M. tuberculosis   M. africant	um □ M. bovis □ Other species (specify):							

<sup>\*</sup>Any genotypic test used for diagnosis and species identification (with or without drug-susceptibility testing), e.g. polymerase chain reaction (PCR)-based test, automated nucleic acid amplification test (NAAT) or next generation sequencing.

Drug susceptibility tes	ting:**Please ind	icate the most r	recent resu	Its of the	laboratory tests pe	erformed.	
Date:	<del></del>						
Drug	Susceptible	Resistant		nding	Unknown	Not tested	
Isoniazid (H)							
Rifampicin (R)							
Ethambutol (E)							
Pyrazinamide (Z)							
Levofloxacin (Lfx)							
Moxifloxacin (M)							
` '	_	_			_	<u>_</u>	
Bedaquiline (B)							
Linezolid (L)							
Others (specify):		_		_			
n case of resistance to R ar	id in piease provide	more informati	on:				
*Either phenotypic or genotypi	c test results.						
. TB treatment			Tue		history		
nitial treatment:				Treatment history:  Treatment adherence: □ Adequate □ Poor (specify)			
tart date :					·		
f there is a change at the ti nformation on the current r			If ye	es, please	specify:	□ Yes □ No	
he patient was given	days of med	dication for trav	I		erruptions [ provide further inf	□ Yes □ No formation:	
medication was provided,	please indicate the	date:					
lanned end-date of treatme	ent :						
Current treatment:							
Drug (generic name)	Formulation (mg	g/tab)	Quantity		Frequency	Any comment	
ny additional information:							
ny additional information.							
4. Contact details	of sending aut	hority					
ending authority:				Additional contact (doctor/health facility/other):			
ddress:				Address:			
				Contact person:			
•			1	•			
				mail:			
hone number:			Phone	number:			
his form was complet	ted on [date]:						